Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Santa Montefiore, author (convert) Simon Sebag Montefiore, author and Haaretz journalist;Jerusalem: The Biography was a number one non-fiction Sunday Times bestseller and a global bestseller and won The Jewish Book of the Year Award from the Jewish Book Council; descended from the banker Sir Joseph Sebag-Montefiore, the nephew and heir of the wealthy philanthropist Sir Moses Montefiore, considered by some "the most important Jew of the 19th century". Simon's mother was Phyllis April Jaffé (1927–2019) from the Lithuanian branch of the Jaffe family. The Montefiore family are descended from a line of wealthy Sephardi Jews who were diplomats and bankers all over Europe and who originated from Morocco and Italy. Eric Moonman (29 April 1929 – 22 December 2017) was Labour politician, chair of Poale Zion (Great Britain), president of Zionist Federation of Great Britain and Ireland; author of book The Violent Society; did consultancy work for ITN as expert in counter-terrorism'; appointed as member of the advisory board of the Centre for Counter Terrorism Studies at the Potomac Institute for Policy Studies. Benny Morris (Hebrew: בני מוריס; born 8 December 1948) Israeli historian of British Jewish ancestry;member of the group of Israeli historians known as the "New Historians", a term Morris coined to describe himself and historians Avi Shlaim, Ilan Pappé and Simha Flapan; Morris's work on the Arab–Israeli conflict and especially the Israeli–Palestinian conflict has won praise and criticism from both sides of the political divide. Morris regards himself as a Zionist.
=== In drug discovery and biomedical research === The ability to grow up functional adult tissues indefinitely in culture through Directed differentiation creates new opportunities for drug research. Researchers are able to grow up differentiated cell lines and then test new drugs on each cell type to examine possible interactions in vitro before performing in vivo studies. This is critical in the development of drugs for use in veterinary research because of the possibilities of species-specific interactions. The hope is that having these cell lines available for research use will reduce the need for research animals used because effects on human tissue in vitro will provide insight not normally known before the animal testing phase.
Globally, infants are a group that is especially vulnerable to foodborne disease. The World Health Organization has issued recommendations for the preparation, use and storage of prepared formulas. Breastfeeding remains the best preventive measure for protection from foodborne infections in infants.
President Benjamin Asher (Aaron Eckhart) from being killed. The film was a commercial success; however, writing for The A.V. Club, Ignatiy Vishnevetsky criticized the cheap filmmaking, saying: "The movie periodically cuts to overqualified supporting actors—including Freeman, Melissa Leo, and Robert Forster ... (As it turns out, it's possible to write something that will sound like garbage even when spoken in Freeman's sonorous voice.)" Next, Freeman reprised his role as Thaddeus Bradley, starring in Now You See Me 2 (2016), the sequel to Now You See Me, the sequel grossing a successful $334.9 million worldwide. Finally, he had a leading role in the historical drama Ben-Hur, the fifth film adaptation of the 1880 novel Ben-Hur: A Tale of the Christ by Lew Wallace. Freeman expressed interest in playing Sheik Ilderim, a wealthy Nubian sheik, stating: "This character has quite a bit of power in the story. And I like playing power. It's something about my own personal ego." Ben-Hur turned out to be one of 2016's biggest box-office bombs.
Monocryl is a synthetic, absorbable suture manufactured in Cornelia, Georgia, USA, and trademarked by Ethicon. It is composed of poliglecaprone 25, which is a copolymer of glycolide and ε-caprolactone. It comes both dyed (violet) and undyed (clear) and is an absorbable monofilament suture. It is generally used for soft-tissue approximation and ligation. It is used frequently for subcuticular dermis closures of the face. It has less of a tendency to exit through the skin after it breaks down, in contrast to Vicryl. It is contraindicated for use in cardiovascular and neurologic tissues and for usage in ophthalmic and microsurgery. The use of poliglecaprone suture may be inappropriate in patients who are older, malnourished, or debilitated, as well as in patients with conditions that may delay wound healing. Monocryl has a low tissue reactivity, maintains high tensile strength, and has a half-life of 7 to 14 days. At 1 week, its in vivo tensile strength is at 50–60% undyed (60–70% dyed), 20–30% undyed (30–40% dyed) at two weeks, and essentially completely hydrolyzed by 91–119 days. When removed from the package, it has a high degree of "memory", or coil. It is slippery, making it easier to pass than a braided suture. It has a consistency close to nylon suture material. It is rarely used for percutaneous skin closure and is not used in areas of high tension (e.g., fascia).
Sources: en.wikipedia.org
=== Aftermarket TPMS === Aftermarket TPMS systems are designed to be retrofitted to vehicles that were not originally equipped with the technology. These systems are available for a wide range of vehicles, from bicycles and trailers to heavy-duty trucks. In commercial fleets, aftermarket TPMS are used as part of fleet digitalization. The sensors on each tire wirelessly transmit real-time pressure and temperature data to a GPS tracking unit in the vehicle. This data is then relayed to a fleet management software platform, allowing fleet managers to remotely monitor tire health, receive alerts for under-inflation, and help prevent blowouts or excessive fuel consumption.
== Preparatory meetings == Sherpa meetings took place in Versailles, Aix-en-Provence, Toulouse, and Évian from January to June 2026 and focused on the main issues to be submitted to the leaders. Representatives from Brazil, India, Kenya and South Korea also took part in these meetings. G7 foreign ministers met at Vaux-de-Cernay Abbey on 26 and 27 March 2026, where they issued a joint statement calling for an "immediate cessation of attacks against civilians and civilian infrastructure" in Iran. G7 environment ministers met on 23 and 24 April 2026 in Paris where they discussed a range of topics leading to four G7 consensus declarations on marine protected areas; illegal, unreported, and unregulated fishing; desertification; and water pollution. France, as G7 president, also issued two declarations on biodiversity finance and resilience in the real estate sector. G7 trade ministers met in Paris on 5 and 6 May 2026, where they discussed global value chain pressures, non-market policies, economic coercion, critical mineral supply chains, WTO reform and cross-border e-commerce. G7 finance ministers and central bank governors met on 18 and 19 May 2026 in Paris where they discussed global economic tensions, bond market volatility, trade strains and the coordination of critical raw material supplies. The G7 labour and employment ministers met at the headquarters of the International Labour Organization in Geneva on 9 June 2026.
== Uses == Chemical analyses have shown that the plant parts are rich in compounds such as amentoflavone, cupressuflavone, and isoorientin. Its extracts are traditionally believed to be antibacterial, anti-inflammatory, antioxidant, antitumor, radioprotective, chemoprotective, antiangiogenetic, wound-healing, immunomodulatory, anti-diabetic, and cardioprotective in nature.
=== UDP-GalNAc synthesis === Human and selected bacterial GALE isoforms bind UDP-GlcNAc, reversibly catalyzing its conversion to UDP-GalNAc. A family of glycosyltransferases known as UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosamine transferases (ppGaNTases) transfers GalNAc from UDP-GalNAc to glycoprotein serine and threonine residues. ppGaNTase-mediated glycosylation regulates protein sorting, ligand signaling, resistance to proteolytic attack, and represents the first committed step in mucin biosynthesis.
Beyond p53, in cancer, many oncogenes and tumor suppressors have been discovered to be SUMOylated in order for the cancer to progress or not, with each SUMOylation event having one of a variety of effects. When IκB is SUMOylated, the SUMO post-translational modification outcompetes ubiquitination, protecting it from degradation, and by extension, the transcription factor NF-κB is bound in a complex with IκB, preventing the expression of genes that may otherwise cause cells with DNA damage to apoptose. In hypoxic conditions as arise in some cancers, HIF-1α, which is usually SUMOylated followed by subsequent ubiquitination and degradation through the von Hippel-Lindau tumor suppressor's ubiquitin ligase activity, is instead deSUMOylated thereby promoting survival of the tumorigenic cells. The fallout from deSUMOylation of HIF-1α includes promotion of MMPs which are understood to contribute to the progression of EMT, a hallmark of cancer. In atherosclerosis, both p53 and ERK5 are SUMOylated by the stimulus of disturbed blood flow. The stimulus is transduced by the activation of a serine/threonine kinsase called p90RSK, which phosphorylates the human SUMO protease SENP2 at the throenine amino acid residue 368. That phosphorylation is sufficient for the delocalization of the SENP2 from the nucleus. The effects of this phosphorylation-dependent SENP2 inhibition by nuclear export include the SUMOylation of p53 which leads to endothelial cell apoptosis, and SUMOylation of ERK5 which leads to inflammation.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.